There is no scientific evidence that HCG is effective in the treatment of obesity. The meta-analysis found insufficient evidence supporting the claims that HCG is effective in altering fat-distribution, hunger reduction, or in inducing a feeling of well-being. The authors stated “…the use of HCG should be regarded as an inappropriate therapy for weight reduction…” In the authors opinion, “Pharmacists and physicians should be alert on the use of HCG for Simeons therapy. The results of this meta-analysis support a firm standpoint against this improper indication. Restraints on physicians practicing this therapy can be based on our findings.”
The level of hCG in the blood is often used as part of a screening for birth defects in a maternal serum triple or quadruple screening test . These tests are usually done between 15 and 20 weeks of pregnancy to check the levels of three or four substances in a pregnant woman's blood. The triple screen checks hCG, alpha-fetoprotein (AFP), and a type of estrogen (unconjugated estriol, or uE3). The quad screen checks these substances and the level of the hormone inhibin A. The levels of these substances-along with a woman's age and other factors-help the doctor figure out the chance that the baby may have certain problems or birth defects.
Human chorionic gonadotropin is used for infertility treatments and is classified in FDA pregnancy category X and is contraindicated after conception has occurred. When administered to mice, animal derived formulations of exogenous HCG have induced a high incidence of external congenital anomalies. While animal data are not always indicative of the response in human gestation, the potential for serious fetal harm cannot be excluded. Therefore, pregnancy should be ruled out prior to the administration of HCG with each fertility treatment course. In addition to potential effects on the fetus, protocols using HCG inherently increase the risk of multiple gestation and the risks associated with such 5